The Value of Anti-Müllerian Hormone in Predicting Ovulation Induced by Aromatase Inhibitors in Women With Polycystic Ovary Syndrome
This study aimed to evaluate the value of anti-Müllerian hormone (AMH) in predicting ovulation induced by aromatase inhibitors (AI) and pregnancy outcomes in women with polycystic ovary syndrome (PCOS). From January 2018 to December 2020, this prospective cohort study enrolled women with PCOS aged b...
Gespeichert in:
| Veröffentlicht in: | Journal of obstetrics and gynaecology Canada 2023-11, Vol.45 (11), p.102183-102183, Article 102183 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102183 |
|---|---|
| container_issue | 11 |
| container_start_page | 102183 |
| container_title | Journal of obstetrics and gynaecology Canada |
| container_volume | 45 |
| creator | Le, Nguyen Sa Viet Le, Minh Tam Tran, Nhu Quynh Thi Nguyen, Quoc Huy Vu Cao, Thanh Ngoc |
| description | This study aimed to evaluate the value of anti-Müllerian hormone (AMH) in predicting ovulation induced by aromatase inhibitors (AI) and pregnancy outcomes in women with polycystic ovary syndrome (PCOS).
From January 2018 to December 2020, this prospective cohort study enrolled women with PCOS aged between 18 and 45 years who underwent ovulation induction using AI protocol and intrauterine insemination (IUI) for infertility at a Center for Reproductive Endocrinology and Infertility, University Hospital. Receiver operating characteristic curves were used to estimate the chance of ovulation responses and pregnancy outcomes.
In total, 64% of 65 women with PCOS were recruited following AI treatment, and the clinical pregnancy rate was 19.4% following IUI. Patients who experienced ovulation had a lower mean serum AMH concentration than non-responders (7.11 ng/mL vs. 8.95 ng/mL, respectively), but the difference was not statistically significant. Between the pregnancy and non-pregnancy groups, statistically significant differences in AMH concentrations were observed (8.71 ng/mL vs. 6.73 ng/mL, respectively, P = 0.040). The area under the curve of the receiver operating characteristic for non-ovulation prediction was 0.445, 95% CI (0.284–0.606) with P = 0.467, and for clinical pregnancy was 0.735, 95% CI (0.561–0.910) with P = 0.104.
In women with PCOS, the AMH level does not predict ovarian responsiveness to AI treatment, but it does predict the success of IUI cycles.
Cette étude visait à évaluer l’utilité du dosage de l’hormone anti-müllérienne (AMH) pour prédire l’induction de l’ovulation par inhibiteur de l’aromatase (IA) et la probabilité de grossesse chez les femmes atteintes du syndrome des ovaires polykystiques (SOPK).
Dans cette étude de cohorte prospective menée de janvier 2018 à décembre 2020, les chercheurs ont recruté les femmes de 18 à 45 ans atteintes du SOPK qui se sont soumises à une induction de l’ovulation par protocole d’IA suivie d’une insémination intra-utérine (IIU) pour le traitement de l’infertilité dans le centre d’endocrinologie de la reproduction et d’infertilité d’un hôpital universitaire. Les courbes d’efficacité du récepteur (ROC) ont été utilisées pour estimer les probabilités d’ovulation et de grossesse.
Au total, 64 % des 65 femmes atteintes du SOPK ont été recrutées après le protocole d’IA, et le taux de grossesses cliniques s’est élevé à 19,4 % après l’IIU. Les patientes qui ont ovulé avaient une plus faible concentration sériqu |
| doi_str_mv | 10.1016/j.jogc.2023.07.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2838254594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1701216323004802</els_id><sourcerecordid>2838254594</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-8238209675b420db5765bb33a12398b66f8962b7f97380daaeecac13f3a7332e3</originalsourceid><addsrcrecordid>eNp9kMFu1DAQhn0A0VJ4AQ7IRy4JtmcTJxKXVUVppaJWosDRsp1J16vELrZTKXceixsvhldbOHKZkUb__8_MR8gbzmrOePt-X-_Dva0FE1AzWTMGz8gpl4xXgrdwQl6mtGeskSD7F-QE5KaBputPyc-7HdJvelqQhpFufXbV59-_pgmj055ehjgHj9R5ehtxcDY7f09vHpdJZxc8vfLDYnGgZqXbGGaddcIy3Dnjcojp4PseZizV5R29DdNq15SdLRE6rvTL6odiw1fk-ainhK-f-hn5evHx7vyyur75dHW-va4sMJmrTkAnWN_KxmwEG0wj28YYAM0F9J1p27HrW2Hk2Evo2KA1otWWwwhaAgiEM_LumPsQw48FU1azSxanSXsMS1KiKwuaTdNvilQcpTaGlCKO6iG6uRytOFMH4mqvDsTVgbhiUhXixfT2KX8xMw7_LH9xF8GHowDLl48Oo0rWoS8IXUSb1RDc__L_APuVldg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2838254594</pqid></control><display><type>article</type><title>The Value of Anti-Müllerian Hormone in Predicting Ovulation Induced by Aromatase Inhibitors in Women With Polycystic Ovary Syndrome</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Le, Nguyen Sa Viet ; Le, Minh Tam ; Tran, Nhu Quynh Thi ; Nguyen, Quoc Huy Vu ; Cao, Thanh Ngoc</creator><creatorcontrib>Le, Nguyen Sa Viet ; Le, Minh Tam ; Tran, Nhu Quynh Thi ; Nguyen, Quoc Huy Vu ; Cao, Thanh Ngoc</creatorcontrib><description>This study aimed to evaluate the value of anti-Müllerian hormone (AMH) in predicting ovulation induced by aromatase inhibitors (AI) and pregnancy outcomes in women with polycystic ovary syndrome (PCOS).
From January 2018 to December 2020, this prospective cohort study enrolled women with PCOS aged between 18 and 45 years who underwent ovulation induction using AI protocol and intrauterine insemination (IUI) for infertility at a Center for Reproductive Endocrinology and Infertility, University Hospital. Receiver operating characteristic curves were used to estimate the chance of ovulation responses and pregnancy outcomes.
In total, 64% of 65 women with PCOS were recruited following AI treatment, and the clinical pregnancy rate was 19.4% following IUI. Patients who experienced ovulation had a lower mean serum AMH concentration than non-responders (7.11 ng/mL vs. 8.95 ng/mL, respectively), but the difference was not statistically significant. Between the pregnancy and non-pregnancy groups, statistically significant differences in AMH concentrations were observed (8.71 ng/mL vs. 6.73 ng/mL, respectively, P = 0.040). The area under the curve of the receiver operating characteristic for non-ovulation prediction was 0.445, 95% CI (0.284–0.606) with P = 0.467, and for clinical pregnancy was 0.735, 95% CI (0.561–0.910) with P = 0.104.
In women with PCOS, the AMH level does not predict ovarian responsiveness to AI treatment, but it does predict the success of IUI cycles.
Cette étude visait à évaluer l’utilité du dosage de l’hormone anti-müllérienne (AMH) pour prédire l’induction de l’ovulation par inhibiteur de l’aromatase (IA) et la probabilité de grossesse chez les femmes atteintes du syndrome des ovaires polykystiques (SOPK).
Dans cette étude de cohorte prospective menée de janvier 2018 à décembre 2020, les chercheurs ont recruté les femmes de 18 à 45 ans atteintes du SOPK qui se sont soumises à une induction de l’ovulation par protocole d’IA suivie d’une insémination intra-utérine (IIU) pour le traitement de l’infertilité dans le centre d’endocrinologie de la reproduction et d’infertilité d’un hôpital universitaire. Les courbes d’efficacité du récepteur (ROC) ont été utilisées pour estimer les probabilités d’ovulation et de grossesse.
Au total, 64 % des 65 femmes atteintes du SOPK ont été recrutées après le protocole d’IA, et le taux de grossesses cliniques s’est élevé à 19,4 % après l’IIU. Les patientes qui ont ovulé avaient une plus faible concentration sérique d’AMH que celles qui n’ont pas ovulé (7,11 ng/ml p/r à 8,95 ng/ml, respectivement), mais la différence n’est pas statistiquement significative. Entre les groupes grossesse et sans grossesse, une différence statistiquement significative de concentration de l’AMH a été observée (8,71 ng/ml p/r à 6,73 ng/ml, respectivement, P = 0,040). L’aire sous la courbe ROC pour la prédiction de la non-ovulation était de 0,445 (IC à 95 % : 0,284–0,606; P = 0,467) et de 0,735 pour la prédiction de la grossesse clinique (IC à 95 % : 0,561–0,910; P = 0,104).
Chez les femmes atteintes du SOPK, le dosage de l’AMH ne permet pas de prédire la réponse ovarienne au traitement par IA, mais il permet de prédire la probabilité de grossesse clinique suivant l’IIU.</description><identifier>ISSN: 1701-2163</identifier><identifier>DOI: 10.1016/j.jogc.2023.07.003</identifier><identifier>PMID: 37453589</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Anti-Mullerian Hormone ; aromatase Inhibitors ; Aromatase Inhibitors - therapeutic use ; Female ; Humans ; Infertility, Female - drug therapy ; Middle Aged ; ovulation induction ; Ovulation Induction - methods ; Ovulation Prediction ; polycystic ovary syndrome ; Polycystic Ovary Syndrome - drug therapy ; Pregnancy ; Prospective Studies ; Young Adult</subject><ispartof>Journal of obstetrics and gynaecology Canada, 2023-11, Vol.45 (11), p.102183-102183, Article 102183</ispartof><rights>2023 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada</rights><rights>Copyright © 2023 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-8238209675b420db5765bb33a12398b66f8962b7f97380daaeecac13f3a7332e3</cites><orcidid>0000-0001-6225-3108</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37453589$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Le, Nguyen Sa Viet</creatorcontrib><creatorcontrib>Le, Minh Tam</creatorcontrib><creatorcontrib>Tran, Nhu Quynh Thi</creatorcontrib><creatorcontrib>Nguyen, Quoc Huy Vu</creatorcontrib><creatorcontrib>Cao, Thanh Ngoc</creatorcontrib><title>The Value of Anti-Müllerian Hormone in Predicting Ovulation Induced by Aromatase Inhibitors in Women With Polycystic Ovary Syndrome</title><title>Journal of obstetrics and gynaecology Canada</title><addtitle>J Obstet Gynaecol Can</addtitle><description>This study aimed to evaluate the value of anti-Müllerian hormone (AMH) in predicting ovulation induced by aromatase inhibitors (AI) and pregnancy outcomes in women with polycystic ovary syndrome (PCOS).
From January 2018 to December 2020, this prospective cohort study enrolled women with PCOS aged between 18 and 45 years who underwent ovulation induction using AI protocol and intrauterine insemination (IUI) for infertility at a Center for Reproductive Endocrinology and Infertility, University Hospital. Receiver operating characteristic curves were used to estimate the chance of ovulation responses and pregnancy outcomes.
In total, 64% of 65 women with PCOS were recruited following AI treatment, and the clinical pregnancy rate was 19.4% following IUI. Patients who experienced ovulation had a lower mean serum AMH concentration than non-responders (7.11 ng/mL vs. 8.95 ng/mL, respectively), but the difference was not statistically significant. Between the pregnancy and non-pregnancy groups, statistically significant differences in AMH concentrations were observed (8.71 ng/mL vs. 6.73 ng/mL, respectively, P = 0.040). The area under the curve of the receiver operating characteristic for non-ovulation prediction was 0.445, 95% CI (0.284–0.606) with P = 0.467, and for clinical pregnancy was 0.735, 95% CI (0.561–0.910) with P = 0.104.
In women with PCOS, the AMH level does not predict ovarian responsiveness to AI treatment, but it does predict the success of IUI cycles.
Cette étude visait à évaluer l’utilité du dosage de l’hormone anti-müllérienne (AMH) pour prédire l’induction de l’ovulation par inhibiteur de l’aromatase (IA) et la probabilité de grossesse chez les femmes atteintes du syndrome des ovaires polykystiques (SOPK).
Dans cette étude de cohorte prospective menée de janvier 2018 à décembre 2020, les chercheurs ont recruté les femmes de 18 à 45 ans atteintes du SOPK qui se sont soumises à une induction de l’ovulation par protocole d’IA suivie d’une insémination intra-utérine (IIU) pour le traitement de l’infertilité dans le centre d’endocrinologie de la reproduction et d’infertilité d’un hôpital universitaire. Les courbes d’efficacité du récepteur (ROC) ont été utilisées pour estimer les probabilités d’ovulation et de grossesse.
Au total, 64 % des 65 femmes atteintes du SOPK ont été recrutées après le protocole d’IA, et le taux de grossesses cliniques s’est élevé à 19,4 % après l’IIU. Les patientes qui ont ovulé avaient une plus faible concentration sérique d’AMH que celles qui n’ont pas ovulé (7,11 ng/ml p/r à 8,95 ng/ml, respectivement), mais la différence n’est pas statistiquement significative. Entre les groupes grossesse et sans grossesse, une différence statistiquement significative de concentration de l’AMH a été observée (8,71 ng/ml p/r à 6,73 ng/ml, respectivement, P = 0,040). L’aire sous la courbe ROC pour la prédiction de la non-ovulation était de 0,445 (IC à 95 % : 0,284–0,606; P = 0,467) et de 0,735 pour la prédiction de la grossesse clinique (IC à 95 % : 0,561–0,910; P = 0,104).
Chez les femmes atteintes du SOPK, le dosage de l’AMH ne permet pas de prédire la réponse ovarienne au traitement par IA, mais il permet de prédire la probabilité de grossesse clinique suivant l’IIU.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-Mullerian Hormone</subject><subject>aromatase Inhibitors</subject><subject>Aromatase Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Infertility, Female - drug therapy</subject><subject>Middle Aged</subject><subject>ovulation induction</subject><subject>Ovulation Induction - methods</subject><subject>Ovulation Prediction</subject><subject>polycystic ovary syndrome</subject><subject>Polycystic Ovary Syndrome - drug therapy</subject><subject>Pregnancy</subject><subject>Prospective Studies</subject><subject>Young Adult</subject><issn>1701-2163</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFu1DAQhn0A0VJ4AQ7IRy4JtmcTJxKXVUVppaJWosDRsp1J16vELrZTKXceixsvhldbOHKZkUb__8_MR8gbzmrOePt-X-_Dva0FE1AzWTMGz8gpl4xXgrdwQl6mtGeskSD7F-QE5KaBputPyc-7HdJvelqQhpFufXbV59-_pgmj055ehjgHj9R5ehtxcDY7f09vHpdJZxc8vfLDYnGgZqXbGGaddcIy3Dnjcojp4PseZizV5R29DdNq15SdLRE6rvTL6odiw1fk-ainhK-f-hn5evHx7vyyur75dHW-va4sMJmrTkAnWN_KxmwEG0wj28YYAM0F9J1p27HrW2Hk2Evo2KA1otWWwwhaAgiEM_LumPsQw48FU1azSxanSXsMS1KiKwuaTdNvilQcpTaGlCKO6iG6uRytOFMH4mqvDsTVgbhiUhXixfT2KX8xMw7_LH9xF8GHowDLl48Oo0rWoS8IXUSb1RDc__L_APuVldg</recordid><startdate>202311</startdate><enddate>202311</enddate><creator>Le, Nguyen Sa Viet</creator><creator>Le, Minh Tam</creator><creator>Tran, Nhu Quynh Thi</creator><creator>Nguyen, Quoc Huy Vu</creator><creator>Cao, Thanh Ngoc</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6225-3108</orcidid></search><sort><creationdate>202311</creationdate><title>The Value of Anti-Müllerian Hormone in Predicting Ovulation Induced by Aromatase Inhibitors in Women With Polycystic Ovary Syndrome</title><author>Le, Nguyen Sa Viet ; Le, Minh Tam ; Tran, Nhu Quynh Thi ; Nguyen, Quoc Huy Vu ; Cao, Thanh Ngoc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-8238209675b420db5765bb33a12398b66f8962b7f97380daaeecac13f3a7332e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-Mullerian Hormone</topic><topic>aromatase Inhibitors</topic><topic>Aromatase Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Infertility, Female - drug therapy</topic><topic>Middle Aged</topic><topic>ovulation induction</topic><topic>Ovulation Induction - methods</topic><topic>Ovulation Prediction</topic><topic>polycystic ovary syndrome</topic><topic>Polycystic Ovary Syndrome - drug therapy</topic><topic>Pregnancy</topic><topic>Prospective Studies</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Le, Nguyen Sa Viet</creatorcontrib><creatorcontrib>Le, Minh Tam</creatorcontrib><creatorcontrib>Tran, Nhu Quynh Thi</creatorcontrib><creatorcontrib>Nguyen, Quoc Huy Vu</creatorcontrib><creatorcontrib>Cao, Thanh Ngoc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of obstetrics and gynaecology Canada</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Le, Nguyen Sa Viet</au><au>Le, Minh Tam</au><au>Tran, Nhu Quynh Thi</au><au>Nguyen, Quoc Huy Vu</au><au>Cao, Thanh Ngoc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Value of Anti-Müllerian Hormone in Predicting Ovulation Induced by Aromatase Inhibitors in Women With Polycystic Ovary Syndrome</atitle><jtitle>Journal of obstetrics and gynaecology Canada</jtitle><addtitle>J Obstet Gynaecol Can</addtitle><date>2023-11</date><risdate>2023</risdate><volume>45</volume><issue>11</issue><spage>102183</spage><epage>102183</epage><pages>102183-102183</pages><artnum>102183</artnum><issn>1701-2163</issn><abstract>This study aimed to evaluate the value of anti-Müllerian hormone (AMH) in predicting ovulation induced by aromatase inhibitors (AI) and pregnancy outcomes in women with polycystic ovary syndrome (PCOS).
From January 2018 to December 2020, this prospective cohort study enrolled women with PCOS aged between 18 and 45 years who underwent ovulation induction using AI protocol and intrauterine insemination (IUI) for infertility at a Center for Reproductive Endocrinology and Infertility, University Hospital. Receiver operating characteristic curves were used to estimate the chance of ovulation responses and pregnancy outcomes.
In total, 64% of 65 women with PCOS were recruited following AI treatment, and the clinical pregnancy rate was 19.4% following IUI. Patients who experienced ovulation had a lower mean serum AMH concentration than non-responders (7.11 ng/mL vs. 8.95 ng/mL, respectively), but the difference was not statistically significant. Between the pregnancy and non-pregnancy groups, statistically significant differences in AMH concentrations were observed (8.71 ng/mL vs. 6.73 ng/mL, respectively, P = 0.040). The area under the curve of the receiver operating characteristic for non-ovulation prediction was 0.445, 95% CI (0.284–0.606) with P = 0.467, and for clinical pregnancy was 0.735, 95% CI (0.561–0.910) with P = 0.104.
In women with PCOS, the AMH level does not predict ovarian responsiveness to AI treatment, but it does predict the success of IUI cycles.
Cette étude visait à évaluer l’utilité du dosage de l’hormone anti-müllérienne (AMH) pour prédire l’induction de l’ovulation par inhibiteur de l’aromatase (IA) et la probabilité de grossesse chez les femmes atteintes du syndrome des ovaires polykystiques (SOPK).
Dans cette étude de cohorte prospective menée de janvier 2018 à décembre 2020, les chercheurs ont recruté les femmes de 18 à 45 ans atteintes du SOPK qui se sont soumises à une induction de l’ovulation par protocole d’IA suivie d’une insémination intra-utérine (IIU) pour le traitement de l’infertilité dans le centre d’endocrinologie de la reproduction et d’infertilité d’un hôpital universitaire. Les courbes d’efficacité du récepteur (ROC) ont été utilisées pour estimer les probabilités d’ovulation et de grossesse.
Au total, 64 % des 65 femmes atteintes du SOPK ont été recrutées après le protocole d’IA, et le taux de grossesses cliniques s’est élevé à 19,4 % après l’IIU. Les patientes qui ont ovulé avaient une plus faible concentration sérique d’AMH que celles qui n’ont pas ovulé (7,11 ng/ml p/r à 8,95 ng/ml, respectivement), mais la différence n’est pas statistiquement significative. Entre les groupes grossesse et sans grossesse, une différence statistiquement significative de concentration de l’AMH a été observée (8,71 ng/ml p/r à 6,73 ng/ml, respectivement, P = 0,040). L’aire sous la courbe ROC pour la prédiction de la non-ovulation était de 0,445 (IC à 95 % : 0,284–0,606; P = 0,467) et de 0,735 pour la prédiction de la grossesse clinique (IC à 95 % : 0,561–0,910; P = 0,104).
Chez les femmes atteintes du SOPK, le dosage de l’AMH ne permet pas de prédire la réponse ovarienne au traitement par IA, mais il permet de prédire la probabilité de grossesse clinique suivant l’IIU.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>37453589</pmid><doi>10.1016/j.jogc.2023.07.003</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6225-3108</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1701-2163 |
| ispartof | Journal of obstetrics and gynaecology Canada, 2023-11, Vol.45 (11), p.102183-102183, Article 102183 |
| issn | 1701-2163 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2838254594 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Anti-Mullerian Hormone aromatase Inhibitors Aromatase Inhibitors - therapeutic use Female Humans Infertility, Female - drug therapy Middle Aged ovulation induction Ovulation Induction - methods Ovulation Prediction polycystic ovary syndrome Polycystic Ovary Syndrome - drug therapy Pregnancy Prospective Studies Young Adult |
| title | The Value of Anti-Müllerian Hormone in Predicting Ovulation Induced by Aromatase Inhibitors in Women With Polycystic Ovary Syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T15%3A42%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Value%20of%20Anti-M%C3%BCllerian%20Hormone%20in%20Predicting%20Ovulation%20Induced%20by%20Aromatase%20Inhibitors%20in%20Women%20With%20Polycystic%20Ovary%20Syndrome&rft.jtitle=Journal%20of%20obstetrics%20and%20gynaecology%20Canada&rft.au=Le,%20Nguyen%20Sa%20Viet&rft.date=2023-11&rft.volume=45&rft.issue=11&rft.spage=102183&rft.epage=102183&rft.pages=102183-102183&rft.artnum=102183&rft.issn=1701-2163&rft_id=info:doi/10.1016/j.jogc.2023.07.003&rft_dat=%3Cproquest_cross%3E2838254594%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2838254594&rft_id=info:pmid/37453589&rft_els_id=S1701216323004802&rfr_iscdi=true |